AB SCIENCE was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science.
It makes us very proud and confident that, after only 7 years of existence, AB SCIENCE has been the first and so far only independent emerging pharmaceutical company to have registered a tyrosine kinase inhibitor, in a peer group of very large multinational companies such as Novartis, Bristol-Myers, or Pfizer.

We have already started the commercialization of the product under the brand of MASIVET in Europe in 2008 , KINAVET in USA in 2010, and our pipeline is well advanced in human medecine with 3 phase 3 on going in pancreatic cancer, GIST and mastocytosis, and 8 phase 2 completed.